Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 etrolizumab maintenance study in TNF-naive moderate-to-severe ulcerative colitis
MOH_2017-07-16_000619Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrolizumab maintenance with Placebo maintenance (2 arms). Primary endpoint: Not reported. Started Jun 2014; status: recruiting.
02
Drugs
Etrolizumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2017-07-16_000619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-16_000619.